改良IVM方法用于多囊卵巢综合征患者小卵泡卵丘-卵母细胞复合体可提高卵母细胞能力和胚胎产出
两项前瞻性研究纳入多囊卵巢综合征患者,评估CNP预成熟培养后FSH+AREG成熟的新IVM方法。新方法使每个卵丘-卵母细胞复合体的减数分裂成熟率升至70%,显著高于常规IVM的49%,可移植第3天胚胎比例从23%升至43%,优质囊胚比例从8%升至18%。
要点
- CNP预成熟培养后FSH+AREG成熟可提高PCOS患者小卵泡卵母细胞成熟率。
- 新方法使可移植第3天胚胎和优质囊胚比例较常规IVM显著增加。
- CNP可阻止减数分裂恢复长达46小时,并保留卵丘-卵母细胞经带突起。
核心结论
- 含CNP预成熟培养后FSH+AREG成熟的IVM策略可提高卵母细胞成熟潜能,增加第3天胚胎和优质囊胚的可获得性。
研究设计与样本
- 第一项前瞻性研究纳入15例多囊卵巢综合征患者,采用同胞卵母细胞评估新IVM培养方法对卵母细胞核成熟及发育能力的影响。
- 第二项前瞻性研究纳入另15例多囊卵巢妇女,表征并优化预成熟培养条件。
- 患者接受3-5天高纯度人绝经期促性腺激素刺激后行IVM治疗,取卵前未使用人绒毛膜促性腺激素扳机。
主要发现
- 含CNP预成熟培养后FSH+AREG成熟使每个卵丘-卵母细胞复合体的减数分裂成熟率升至70%,显著高于常规标准IVM的49%(P ≤ 0.001)。
- 新方法使可移植第3天胚胎比例从23%升至43%(P ≤ 0.001),优质囊胚比例从8%升至18%(P ≤ 0.01)。
- CNP可阻止减数分裂恢复长达46小时,预成熟培养后卵丘-卵母细胞复合体保留经带突起。
- 预成熟培养+IVM获得的囊胚非整倍体率与常规辅助生殖技术囊胚相比未显示升高。
局限性
- 新IVM方法在多囊卵巢综合征患者中测试的卵母细胞来自本身发育潜能低的小窦卵泡。
- 该系统需在不同(较大)卵泡大小的卵丘-卵母细胞复合体中进行验证,可能涉及进一步调整预成熟培养条件。
- 作为人类IVM治疗的新策略,其整体效率需在大规模前瞻性随机对照试验中确认。
- 在非多囊卵巢综合征的不孕患者(如癌症患者)中的进一步应用仍有待评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Are meiotic and developmental competence of human oocytes from small (2-8 mm) antral follicles improved by applying an optimized IVM method involving a prematuration step in presence of C-Type Natriuretic Peptide (CNP) followed by a maturation step in presence of FSH and Amphiregulin (AREG)? SUMMARY ANSWER: A strategy involving prematuration culture (PMC) in the presence of CNP followed by IVM using FSH + AREG increases oocyte maturation potential leading to a higher availability of Day 3 embryos and good-quality blastocysts for single embryo transfer. WHAT IS KNOWN ALREADY: IVM is a minimal-stimulation ART with reduced hormone-related side effects and risks for the patients, but the approach is not widely used because of an efficiency gap compared to conventional ART. In vitro systems that enhance synchronization of nuclear and cytoplasmic maturation before the meiotic trigger are crucial to optimize human IVM systems. However, previous PMC attempts have failed in sustaining cumulus-oocyte connections throughout the culture period, which prohibited a normal cumulus-oocyte communication and precluded an adequate response by the cumulus-oocyte complex (COC) to the meiotic trigger. STUDY DESIGN, SIZE, DURATION: A first prospective study involved sibling oocytes from a group of 15 patients with polycystic ovary syndrome (PCOS) to evaluate effects of a new IVM culture method on oocyte nuclear maturation and their downstream developmental competence. A second prospective study in an additional series of 15 women with polycystic ovaries characterized and fine-tuned the culture conditions. PARTICIPANTS/MATERIALS, SETTING, METHODS: Fifteen women with PCOS (according to Rotterdam criteria) underwent IVM treatment after 3-5 days of highly purified human menopausal gonadotropin (HP-hMG) stimulation and no human chorionic gonadotropin (hCG) trigger before oocyte retrieval. A first study was designed with sibling oocytes to prospectively evaluate the impact of an IVM culture method: 24 h PMC with CNP + 30 h IVM with FSH and AREG, on embryo yield, in comparison to the standard (30 h) IVM clinical protocol (Group I, n = 15). A second prospective study was performed in 15 women with polycystic ovaries, to characterize and optimize the PMC conditions (Group II, n = 15). The latter study involved the evaluation of oocyte meiotic arrest, the preservation of cumulus-oocyte transzonal projections (TZPs), the patterns of oocyte chromatin configuration and cumulus cells apoptosis following the 24 and 46 h PMC. Furthermore, oocyte developmental potential following PMC (24 and 46 h) + IVM was also evaluated. The first 20 good-quality blastocysts from PMC followed by IVM were analysed by next generation sequencing to evaluate their aneuploidy rate. MAIN RESULTS AND THE ROLE OF CHANCE: PMC in presence of CNP followed by IVM using FSH and AREG increased the meiotic maturation rate per COC to 70%, which is significantly higher than routine standard IVM (49%; P ≤ 0.001). Hence, with the new system the proportion of COCs yielding transferable Day 3 embryos and good-quality blastocysts increased compared to routine standard IVM (from 23 to 43%; P ≤ 0.001 and from 8 to 18%; P ≤ 0.01, respectively). CNP was able to prevent meiosis resumption for up to 46 h. After PMC, COCs had preserved cumulus-oocyte TZPs. The blastocysts obtained after PMC + IVM did not show increased aneuploidy rates as compared to blastocysts from conventional ART. LIMITATIONS REASONS FOR CAUTION: The novel IVM approach in PCOS patients was tested in oocytes derived from small antral follicles which have an intrinsically low developmental potential. Validation of the system would be required for COCs from different (larger) follicular sizes, which may involve further adjustment of PMC conditions. Furthermore, considering that this is a novel strategy in human IVM treatment, its global efficiency needs to be confirmed in large prospective randomized controlled trials. The further application in infertile patients without PCOS, e.g. cancer patients, remains to be evaluated. WIDER IMPLICATIONS OF THE FINDINGS: The findings of this pilot study suggest that the efficiency gap between IVM and conventional IVF can be reduced by fine-tuning of the culture methods. This novel strategy opens new perspectives for safe and patient-friendly ART in patients with PCOS. STUDY FUNDING/COMPETING INTEREST(S): IVM research at the Vrije Universiteit Brussel has been supported by grants from: the Institute for the Promotion of Innovation by Science and Technology in Flanders (Agentschap voor Innovatie door Wetenschap en Technologie-IWT, project 110680); the Fund for Research Flanders (Fonds Wetenschappelijk Onderzoek-Vlaanderen-FWO, project G.0343.13), the Belgian Foundation Against Cancer (HOPE project, Dossier C69). The authors have no conflicts of interest.
引用
- Sánchez F, Lolicato F, Romero S, et al. An improved IVM method for cumulus-oocyte complexes from small follicles in polycystic ovary syndrome patients enhances oocyte competence and embryo yield. Hum Reprod. 2017. PMID: 28938744. doi:10.1093/humrep/dex262
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。